Tag Archives: Aurinia Pharmaceuticals

Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More

If you’re keeping track, FDA drug approvals have been on a tear in the past month with several decisions coming well ahead of their targeted dates. And then there’s Sarepta Therapeutics. Late Thursday, the FDA announced approval of the Cambridge, MA, biotech’s drug for Duchenne muscular dystrophy in patients who have a specific mutation. The […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3 study. Aurinia Pharmaceuticals (NASDAQ: AUPH) is testing its drug, voclosporin, as a treatment for lupus nephritis (LN), which can occur when lupus, an autoimmune disorder,  causes the immune system […]

Posted in National, National blog main | Tagged , , , , | Comments Off on Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

When the Olympics roll around, many watchers get into a sport they previously hadn’t thought much about. This time for me, it’s volleyball. The men’s and women’s games, both indoor and beach versions, are fast, aggressive, with lightning-quick adjustments and subtle teamwork required every time a ball is dug out and popped in the air. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

Amid String of Exits for VenBio, a Founding Partner Leaves, Too

With three acquisitions of its portfolio companies, San Francisco biotech investment firm venBio has had a few good exits recently. Now one of its partners is exiting, too. Kurt Von Emster, one of four venBio founders, has decamped for Abingworth, a life science venture firm with a much longer history and global reach. Abingworth made […]

Posted in National blog main, San Diego blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , | Comments Off on Amid String of Exits for VenBio, a Founding Partner Leaves, Too

As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund

San Francisco life sciences venture firm venBio is making news these days with entrances and exits. Since its $180 million inaugural fund closed in 2011, two of its portfolio companies have become splashy acquisitions, including one last week. Thanks to those exits, venBio’s investors have more than broken even, and the group is now eyeing […]

Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund